CytRx Corp. buy melinda
Start price
11.05.17
/
50%
€2.41
Target price
18.05.17
€3.25
Performance (%)
14.13%
End price
18.05.17
€2.75
Summary
This prediction ended on 18.05.17 with a price of €2.75. The prediction had a final performance of 14.13%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CytRx Corp. | - | - | - | - |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% | 68.627% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% | 116.238% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% | 56.217% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% | 70.924% |
Comments by melinda for this prediction
In the thread CytRx Corp. diskutieren
Gesundheit | Biotechnologie | Vereinigte Staaten
Aldoxorubicine mit Doxorubicin
Krebs Weichteilsarkom feuerfester Krebs